Study: Inhaled Cannabis Provides Long-Term Pain Relief and Reduces Opioid Use in Diabetic Neuropathy Patients
A new study published in the journal Biomedicines has found that inhaled cannabis can provide lasting benefits for patients suffering from painful diabetic neuropathy (DN), a common complication of diabetes that affects up to half of long-term patients.
The five-year observational study followed 52 patients who had failed to respond to at least three conventional pain treatments, including opioids, gabapentin, and duloxetine. After a one-month washout period, patients began inhaling medical-grade cannabis containing 20% THC and less than 1% CBD.
Assessments included pain scales, neuropathic symptom scores, blood sugar control, and medication use. By the end of the study, pain severity scores dropped from an average of 9.0 to 2.0, while pain interference scores fell from 7.5 to 2.2.
No specific quote available in the given text.
Author's summary: Inhaled cannabis reduces pain in diabetic neuropathy patients.
More News
- NBA approves $10 billion Lakers sale to Mark Walter
- Stranger Things 5 Trailer Unleashes All-Out War in Hawkins Ahead of Final Season! | SPIN1038
- Half of Illinois students reading at grade level, fewer in math under loosened standards
- Stranger Things 5 trailer shows way more than we were ready for
- Dean Lewis Shares Statement Following Misconduct Allegations
- City unveils plan for new stage, remodel of Coleman Hawkins Park next spring
- Bank of Canada Cuts Rates, Prioritizing Survival Over Inflation Control - Better Dwelling
- They’re already here: How U.S. corporations have been eroding Canada’s economic sovereignty
- Shares of Navan Down 16% In Long-Awaited IPO Debut
- Jacob Elordi, Sydney Sweeney, & More to Receive 2026 SBIFF Virtuosos Award | News Channel 3-12